脑脉利颗粒联合常规治疗对缺血性脑卒中的临床疗效和安全性Meta分析及试验序贯分析OA
Meta-Analysis and Trial Sequential Analysis of Clinical Effect and Safety of Naomaili Granules Combined with Conventional Treatment for Ischemic Stroke
目的:系统评价脑脉利颗粒联合常规治疗对缺血性脑卒中(IS)的临床疗效和安全性.方法:计算机检索PubMed、EMBASE、Cochrane Library、中国生物医学文献数据库、中国知网、万方、维普、全国优秀硕士博士论文数据库自建库至2025年8月1日有关脑脉利颗粒联合常规治疗干预IS的临床随机对照试验研究文献.采用RevMan5.4软件对临床疗效、安全性指标进行Meta分析、TSA 0.9.5.10 Beta软件对治疗总有效率进行序贯分析.结果:共纳入19项研究,2 014位受试者,试验组1 015例,对照组999例.Meta分析显示:试验组治疗总有效率[RR=1.16,95%CI(1.11,1.21),P<0.000 01]、Barthel 指数(BI)评分[MD=12.02,95%CI(9.45,14.60),P<0.000 01]、改良Rankin(mRS)评分≤2分的比例[RR=1.59,95%CI(1.17,2.17),P=0.003]均高于对照组,美国国立卫生研究院卒中量表(NIHSS)评分[MD=-1.68,95%CI(-1.91,-1.45),P<0.000 01]、mRS评分[MD=-0.36,95%CI(-0.50,-0.21),P<0.000 01]、总胆固醇(TC)[MD=-0.27,95%CI(-0.33,-0.21),P<0.000 01]、甘油三酯(TG)[MD=-0.20,95%CI(-0.24,-0.17),P<0.000 01]、低密度脂蛋白胆固醇(LDL-C)[MD=-0.86,95%CI(-0.93,-0.78),P<0.000 01]、白细胞介素-6(IL-6)[MD=-13.20,95%CI(-17.07,-9.23),P<0.000 01]、肿瘤坏死因子-α(TNF-α)[MD=-8.08,95%CI(-12.11,-4.05),P<0.000 01]、超敏C-反应蛋白(hs-CRP)[MD=-3.03,95%CI(-3.31,-2.74),P<0.000 01]均低于对照组.2组中医证候有效率、高密度脂蛋白胆固醇(HDL-C)、不良反应发生率比较,差异均无统计学意义(P>0.05).试验序贯分析显示:纳入足够多的样本量后,治疗总有效率的累积超过了传统界值和试验序贯分析界值,进一步说明脑脉利颗粒联合常规治疗对IS的临床疗效.结论:与常规治疗相比,脑脉利颗粒联合常规治疗干预IS可提高治疗总有效率,降低NIHSS评分及残疾程度,促进神经功能恢复,同时可调节血脂,抑制炎症反应,药物不良反应发生率无明显增加.
Objective:To systematically evaluate the clinical effect and safety of Naomaili Granules combined with conventional treatment for ischemic stroke(IS).Methods:Computer-based retrieval was conducted in PubMed,EMBASE,Cochrane Library,China Biology Medicine disc(CBM),China National Knowledge Infrastructure(CNKI),Wanfang database,VIP database,and National Excellent Master's and Doctoral Dissertations database from their establishment to August 1,2025.Randomized controlled trials(RCTs)on Naomaili Granules combined with conventional treatment for IS were included.RevMan 5.4 software was used for meta-analysis of clinical effect and safety indicators,and TSA 0.9.5.10 Beta software was applied for trial sequential analysis(TSA)of the total effective rate.Results:A total of 19 studies involving 2 014 subjects were included,with 1 015 cases in the trial group and 999 cases in the control group.Meta-analysis showed that:the total effective rate[relative risk(RR)=1.16,95%confidence interval(CI)(1.11,1.21),P<0.000 01],Barthel Index(BI)score[mean difference(MD)=12.02,95%CI(9.45,14.60),P<0.000 01],and the proportion of patients with modified Rankin Scale(mRS)score≤2[RR=1.59,95%CI(1.17,2.17),P=0.003]in the trial group were significantly higher than those in the control group.In contrast,the National Institutes of Health Stroke Scale(NIHSS)score[MD=-1.68,95%CI(-1.91,-1.45),P<0.000 01],mRS score[MD=-0.36,95%CI(-0.50,-0.21),P<0.000 01],total cholesterol(TC)[MD=-0.27,95%CI(-0.33,-0.21),P<0.000 01],triglycerides(TG)[MD=-0.20,95%CI(-0.24,-0.17),P<0.000 01],low-density lipoprotein cholesterol(LDL-C)[MD=-0.86,95%CI(-0.93,-0.78),P<0.000 01],interleukin-6(IL-6)[MD=-13.20,95%CI(-17.07,-9.23),P<0.000 01],tumor necrosis factor-α(TNF-α)[MD=-8.08,95%CI(-12.11,-4.05),P<0.000 01],and high-sensitivity C-reactive protein(hs-CRP)[MD=-3.03,95%CI(-3.31,-2.74),P<0.000 01]in the trial group were significantly lower than those in the control group.There was no statistically significant difference in the effective rate of traditional Chinese medicine syndromes,interleukin high-density lipoprotein cholesterol(HDL-C),and incidence of adverse reactions between the two groups(P>0.05).TSA results indicated that after including a sufficient sample size,the cumulative Z-value of the total effective rate exceeded both the traditional threshold and the TSA boundary,further confirming the clinical effect of Naomaili Granules combined with conventional treatment for IS.Conclusion:Compared with conventional treatment alone,Naomaili Granules combined with conventional treatment for IS can improve the total effective rate,reduce NIHSS score and disability degree,promote neurological function recovery,regulate blood lipid levels,and inhibit inflammatory responses,without significantly increasing the incidence of adverse reactions.
乔利军;谢骊妍;张竹欣;丘宇慧;刘文琛;章时杰;方浩;范玲玲;李小刚
广州中医药大学第二附属医院,广东 广州 510120广州中医药大学第二临床医学院,广东 广州 510006广州中医药大学第二临床医学院,广东 广州 510006广州中医药大学第二附属医院,广东 广州 510120广州中医药大学第二附属医院,广东 广州 510120广州中医药大学第二附属医院,广东 广州 510120广州中医药大学第二临床医学院,广东 广州 510006广州中医药大学第二临床医学院,广东 广州 510006北京大学第三医院,北京 100191
医药卫生
缺血性脑卒中脑脉利颗粒临床疗效安全性Meta分析试验序贯分析
Ischemic strokeNaomaili GranulesClinical effectSafetyMeta-analysisTrial sequential analysis
《新中医》 2026 (7)
148-157,10
广东省中医药局中医药科研项目(20231117)
评论